SHANGHAI, CHINA--(Marketwire - May 14, 2008) - Sinobiomed Inc. ("Sinobiomed", or the "Company") (OTCBB: SOBM) is pleased to announce that it is launching the Phase II Clinical Trial of its patented malaria vaccine candidate, PfCP2.9, in epidemic areas in Q3 2008.
